<< Back
Jun 17, 2005
MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research
MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research

ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio Bonvini, M.D. and Joseph Panigot.  Commenting on the recent additions, Dr. Scott Koenig, President and CEO of MacroGenics, stated, We could not be more pleased with the hires of Mr. Campbell and Dr. Wilder to our leadership team and are proud to recognize the already significant contributions of Dr. Bonvini and Mr. Panigot.  Their business and scientific expertise are strong assets as MacroGenics enters clinic development and positions the company for continued growth and success.

Mr. Campbell, who most recently served as a senior vice president and the head of life sciences investment banking at Friedman, Billings, Ramsey & Co., Inc. (FBR), will join MacroGenics in July as the companys Chief Financial Officer.  Prior to his association with FBR, Mr. Campbell served as the Chief Financial Officer of EntreMed, Inc., a publicly-traded biopharmaceutical company that develops therapeutic candidates, primarily for the treatment of cancer.  He also has had extensive experience in corporate finance and mergers and acquisitions with leading investment banks and was a co-founder of OsteoArthritis Sciences, Inc., a venture capital-financed drug discovery company.

Dr. Wilder, an expert in autoimmune and inflammatory diseases, was hired by MacroGenics in May as Vice President of Clinical Research.  Prior to joining MacroGenics, Dr. Wilder served as the Vice President of Clinical Development at MedImmune, Inc., a publicly-traded biotech company which, like MacroGenics, focuses its research efforts on infectious diseases, cancer and autoimmune diseases.  Before moving to industry, Dr. Wilder was Chief of the Inflammatory Joint Diseases Program at the National Institutes of Health (NIH), capping a 25-year career with the institution.  He is an author of more than 250 publications. 

Dr. Bonvini, a hematologist by training, is an expert in immunobiology and joined MacroGenics in June 2003.  He has played a vital role in the success of the companys research platform and in November 2004, was promoted to Vice President of Research.  Dr. Bonvini formerly served as Chief of the Laboratory of Immunobiology and Acting Deputy Director of the Division of Monoclonal Antibodies of the Center for Biologics Evaluation and Research at the FDA.  

Mr. Panigot recently was promoted to the position of Vice President of Legal Affairs.  He joined MacroGenics in April 2002 and is responsible for overseeing legal and intellectual property matters and contributing to the business development activities at the company.  Before coming to MacroGenics, Mr. Panigot served as the Director of Business Development and Legal Affairs at MedImmune, Inc. and prior to that was responsible for managing intellectual property and business development at the University of Maryland Biotechnology Institute.  He is licensed to practice law in Maryland, the District of Columbia, and Virginia and is registered to practice before the U.S. Patent and Trademark Office.

About MacroGenics, Inc.

Founded in 2000, MacroGenics is a private venture-backed biotech company based in Rockville, Maryland.  The company focuses on the development, manufacture, and commercialization of biotechnology products, including immunotherapeutics for autoimmune and inflammatory disorders, cancer, and infectious diseases.  MacroGenics core platform includes antibodies against targets on cells involved in immunological and inflammatory disorders or expressed by cancer cells.  The companys proprietary Fc engineering technology offers ways of improving antibody function, such as enhancing its ability to eliminate cancer cells or cells that contribute to autoimmune disorders.  MacroGenics also is developing a therapeutic monoclonal antibody and a vaccine to prevent and treat West Nile virus infections.


Dr. Scott Koenig, President and CEO; KoenigS@macrogenics.com; 301-354-0680

Mr. Michael Richman, COO; RichmanM@macrogenics.com; 301-354-0681